Toxicity
Total of 16 patients were systemically assessed for the toxicities (Table 4). No fatal adverse events and renal toxicity have been observed, and modest adverse effect can be administered at outpatient service. The commonly grade 3 or 4 toxicity-related events were diarrhea (23%), abdominal pain (38%), alopecia (62%), and leucopenia (40%). Grade 1 to 2 vomiting and nausea was easily administered. Generally, grade 3 or 4 diarrhea was manageable if the antidiarrhea medications were routinely used. In this study, 11 patients received Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) for Injection and most patients had mild myelosuppression or febrile neutropenia. Modest hepatic (13%) and cardiac (7%) toxicity has been observed. Several nonspecific symptoms, including mucositis and fatigue, are occurred, and readily managed. None of the patients delayed chemotherapy because of the toxic and side effects of chemotherapy.